Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...
MPR

FDA Grants Priority Review to Centanafadine for ADHD

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.
Medscape

Time to Reconsider FDA Clearance of Trigeminal Nerve Stimulation for ADHD?

A larger trial of trigeminal nerve stimulation in children with ADHD produce results that differ from an earlier pilot study, raising new questions about its efficacy.
Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

Clinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD “This FDA authorization of ...